When was Dyno Therapeutics founded?

Dyno Therapeutics was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is Dyno Therapeutics located?

Dyno Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

Who is the current CEO of Dyno Therapeutics?

Eric Kelsic of Dyno Therapeutics.

How many employees does Dyno Therapeutics have?

As of Apr 30, 2026, the latest employee count at Dyno Therapeutics is 90.

Is Dyno Therapeutics a funded company?

Dyno Therapeutics is a funded company, having raised a total of $109M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 11, 2020.

When was the latest funding round of Dyno Therapeutics?

Dyno Therapeutics' latest funding was a $***** Series A round on May 06, 2021, with participation from 8 investors.

Where does Dyno Therapeutics rank among its competitors?

Dyno Therapeutics ranks 77th amongst 531 active competitors, of which 197 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Strand Therapeutics, which secured $153M in May, 2025.

Who are the top competitors of Dyno Therapeutics?

Dyno Therapeutics' top competitors include Sana Biotechnology, Spark Therapeutics and Fulcrum Therapeutics. Among them, Strand Therapeutics secured the most recent funding round in May, 2025.

Dyno Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of AI-based data-driven adeno-associated virus (AAV) engineering. The company is developing these vectors for safe and targeted in vivo delivery in gene therapies. The company uses a combination of next-generation DNA synthesis of various AAV capsids with high-throughput sequencing and machine learning. The company also maps the relationship between capsid sequence and function and optimizing vectors for improved therapeutic effect.

Website: www.dynotx.com/
Social
Email ID: *****@dynotx.com
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2018

Location

Cambridge, United States

Stage

Series A

Total Funding

$109M in 2 rounds

Latest Funding Round

Series A, May 06, 2021, $*****

Investors

Andreessen Horowitz & 9 more

Ranked

77^th among 531 active competitors

Employee Count

90 as on Apr 30, 2026

Similar Companies

Innovaccer & 2974 more

View Dyno Therapeutics' full profile

Dyno Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Dyno Therapeutics, Inc. CIN: 825528679 , United States, Active	Dec 31, 1999	-	89 (As on Dec 31, 2024)	-
Dyno Therapeutics Inc. CIN: 82-5528679 , United States, Active	Dec 31, 2017	-	38 (As on Dec 31, 2020)	-

Dyno Therapeutics has raised a total funding of $109M over 2 rounds. Its first funding round was on May 11, 2020. Its latest funding round was a Series A round on May 06, 2021 for $*****. 8 investors participated in its latest round. Dyno Therapeutics has 10 institutional investors.

Here is the list of recent funding rounds of Dyno Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 06, 2021	8646419	Series A	4851303	1153964	1289786	1307876
May 11, 2020	9893791	Seed	8584975	4433276	Polaris Partners & 1 more	8801146

Access funding benchmarks and valuations. Sign up today!

View details of Dyno Therapeutics's funding rounds and investors

The founders of Dyno Therapeutics is Eric Kelsic.

Here are the details of Dyno Therapeutics' key team members:

Eric Kelsic: Founder & CEO of Dyno Therapeutics.
Contact Info: 1 email address

View details of Dyno Therapeutics's Founder profiles and Board Members

Dyno Therapeutics' employee count trend

Dyno Therapeutics has 90 employees as of Apr 26. Here is Dyno Therapeutics's employee count trend over the years:

Employee count trend for Dyno Therapeutics

Uncover Dyno Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Dyno Therapeutics include Sana Biotechnology, Spark Therapeutics and Fulcrum Therapeutics. Here is the list of Top 10 competitors of Dyno Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Wellington & 6 others	74/100
3rd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	71/100
4th	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, BB Biotech & 13 others	70/100
5th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	70/100
6th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
7th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, RA Capital Management & 7 others	70/100
8th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 9 others	69/100
9th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
10th	Krystal Biotech 2015, Pittsburgh (United States), Public	Developer of genetic medicines to treat rare diseases	$11.3M	Frazier Life Sciences, Danforth Advisors & 2 others	69/100
77th	Dyno Therapeutics 2018, Cambridge (United States), Series A	Provider of Ai-based data-driven adeno-associated virus (AAV) engineering	$109M	Casdin Capital, Kygo & 8 others	57/100